Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction. (1st January 2019)

• Record Type: Journal Article
• Authors: Ueland, Thor; Kleveland, Ola; Michelsen, Annika E.; Wiseth, Rune; Damås, Jan Kristian; Holven, Kirsten B.; Aukrust, Pål; Gullestad, Lars; Yndestad, Arne; Halvorsen, Bente
• Is Part Of: International journal of cardiology. Volume 274(2019)
• Page Start: 348
• Page End: 350
• Publication Date: 2019-01-01
• Subjects: Lipoprotein(a) -- Acute coronary syndrome -- IL-6 antagonism -- Inflammation; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2018.06.093
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: The IL-6 receptor antagonist tocilizumab has been shown to attenuate the proatherogenic lipoprotein a [Lp(a)] in rheumatoid arthritis. We evaluated if a single dose of tocilizumab reduced Lp(a) in patients with non-ST-elevation myocardial infarction (NSTEMI). Methods: Lp(a) was assessed by immunoassay (n = 117 patients) at 7 consecutive time-points between day 1 and 3 and at 3 and 6 months follow-up. Results: Tocilizumab did not affect Lp(a) at any time-point during the study and was not associated with cardiovascular risk factors. Conclusions: Short-time inhibition of IL-6 with tocilizumab in patients with NSTEMI did not influence Lp(a) levels. Highlights: Anti IL-6 therapy attenuate lipoprotein a in rheumatoid arthritis but the effect in acute coronary syndromes is unknown In a RCT, short-time inhibition of IL-6 with tocilizumab in patients with NSTEMI did not influence lipoprotein a levels Different mechanisms may regulate lipoprotein a in in rheumatoid arthritis compared to CAD